Meanwhile, we predicted that mutations in RB1, ERBB2, and FANCC increased as CD86 expression increased, suggesting that CD86 may be related to radiotherapy and chemotherapy resistance in AML. The gene discussed is ERBB2; the disease is acute myeloid leukemia.